Loading chat...
ND SB2384
Bill
Status
2/10/2023
Primary Sponsor
Jeffery Magrum
Click for details
AI Summary
-
Directs legislative management to study long-term health effects of respiratory syncytial virus vaccines and messenger ribonucleic acid technology vaccines during the 2023-24 interim period
-
Requires study to include input from the department of health and human services
-
Mandates examination of potential health risks of both vaccine types and analysis of treatment and diagnostic costs for individuals suffering physical injury from these vaccines
-
Requires legislative management to report findings, recommendations, and any necessary implementing legislation to the sixty-ninth legislative assembly
Legislative Description
A BILL for an Act to provide for a legislative management study relating to vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology.
Last Action
Second reading, failed to pass, yeas 38 nays 53
4/4/2023